Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.
about
Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3ACYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropionTransdermal delivery of bupropion and its active metabolite, hydroxybupropion: a prodrug strategy as an alternative approachPhenobarbital increases monkey in vivo nicotine disposition and induces liver and brain CYP2B6 proteinInsights into CYP2B6-mediated drug-drug interactionsGene variants in CYP2C19 are associated with altered in vivo bupropion pharmacokinetics but not bupropion-assisted smoking cessation outcomesMolecular characterization of CYP2B6 substratesInfluence of various polymorphic variants of cytochrome P450 oxidoreductase (POR) on drug metabolic activity of CYP3A4 and CYP2B6CYP2B6 non-coding variation associated with smoking cessation is also associated with differences in allelic expression, splicing, and nicotine metabolism independent of common amino-acid changesEffects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteersN-alkylprotoporphyrin formation and hepatic porphyria in dogs after administration of a new antiepileptic drug candidate: mechanism and species specificityBupropion metabolism by human placenta.Design, baseline characteristics, and retention of African American light smokers into a randomized trial involving biological data.In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation.The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans.Synergistically enhanced CYP2B6 inducibility between a polymorphic mutation in CYP2B6 promoter and pregnane X receptor activation.Formation of threohydrobupropion from bupropion is dependent on 11β-hydroxysteroid dehydrogenase 1.Sucralose, a synthetic organochlorine sweetener: overview of biological issuesGenetic Variants of Pregnane X Receptor (PXR) and CYP2B6 Affect the Induction of Bupropion Hydroxylation by Sodium FerulateCYP2B6: new insights into a historically overlooked cytochrome P450 isozymeAnandamide oxidation by wild-type and polymorphically expressed CYP2B6 and CYP2D6.Characterization of CYP2B6 in a CYP2B6-humanized mouse model: inducibility in the liver by phenobarbital and dexamethasone and role in nicotine metabolism in vivoPharmacogenetics: a tool for identifying genetic factors in drug dependence and response to treatmentMetabolism of bupropion by baboon hepatic and placental microsomes.Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase cFunctional coupling of ATP-binding cassette transporter Abcb6 to cytochrome P450 expression and activity in liver.Thr302 is the site for the covalent modification of human cytochrome P450 2B6 leading to mechanism-based inactivation by tert-butylphenylacetyleneApplications of nanomaterials in electrochemical enzyme biosensors.Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials.Biomarkers of Response to Smoking Cessation Pharmacotherapies: Progress to Date.Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins.Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.Transcriptional Regulation of CYP2B6 Expression by Hepatocyte Nuclear Factor 3β in Human Liver Cells.Effect of renal impairment on the pharmacokinetics of bupropion and its metabolitesPharmacogenetic clinical trial of sustained-release bupropion for smoking cessationRisk assessment of mechanism-based inactivation in drug-drug interactions.Compensatory changes in CYP expression in three different toxicology mouse models: CAR-null, Cyp3a-null, and Cyp2b9/10/13-null miceInhibition of bupropion metabolism by selegiline: mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts.Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance
P2860
Q24317436-EB613618-7A42-43AB-BF85-1EFA2C1F6DF8Q24634660-3F4AFBFC-97DA-456C-9866-C7692154D7B2Q24655598-E1B39DDB-7343-4D77-9EB6-2F9F9138B123Q24671717-D9232439-9EE9-4B81-A4AE-3C714D907CF0Q28078857-320424B3-ADAC-4EF9-9AA9-04A292C9F191Q28247305-A5D9138F-2763-415A-8FAC-9B96809F115CQ28282980-E2778588-A83D-45BB-95C7-9444D459AD75Q28484196-4729FC16-44F7-430C-9934-3E761375C63DQ28535164-4745673C-0B15-4DB8-A2AE-B0A322598F57Q28750369-401E6325-A722-4E48-BBCC-E439C816AA3FQ28834645-7460F439-D0D0-4AF2-B907-0C510B08A9DAQ33759322-516E3FB6-F0B3-4995-9627-714D967AA6DAQ33803436-6EBB62AF-B08D-4588-9BC8-6721308D0B65Q33821729-1B55435B-6FF5-4C9E-AA98-F417424EE580Q33955964-BD029A3F-31A8-4957-8D66-78035195FC63Q34169785-D033312A-0239-4926-977C-7CDD3238B3C7Q34310059-E0661736-BAEC-4E33-A748-FF1393BF8DEBQ34353804-3F075FE8-B529-4732-B1B9-2FF7377AC3F2Q34657381-2A2D1BB6-CFE7-42D3-ACB1-825D10250405Q34804191-E1A43262-284C-4EC2-B9ED-A1D72E2DEAFDQ34824471-3E668E89-4599-4C2F-87F1-1616460A0FC2Q34856974-A7B362BF-54C3-4E4D-8061-087F058B358AQ34946016-BC43DBD0-B267-416B-9B7A-B9CEF4787833Q35059965-5F08A5EE-2542-4B67-88D3-D6199D72B95CQ35072047-F35B158E-0742-46E1-8C35-B6BEFECDC53AQ35188159-AD5B674D-5DCD-4DF8-9067-585A86B07DECQ35199452-A4D9F8B8-BD99-4CF1-B00B-6B463D396364Q35579527-794BD41D-2149-4420-AFDE-71D2C5FC86CCQ35678898-F41D8942-6CC7-4312-9165-C740D2FAEDE7Q35679980-C945C7B2-2ED0-488E-852F-76B4027648D6Q35751986-65C59EDA-FBC8-478A-8FF8-E25030B68B8FQ35828228-DCA0EC61-1903-4DAA-BD2A-27817816D5A6Q35846912-85D210F3-FC5A-4138-A107-60CC58C30DB6Q35941376-C1B12895-FA40-444B-AC3A-C36982A18ECDQ36024598-1BEC493C-D975-4AA9-AF7F-D634883F8CF9Q36087706-5F3BB6B8-F57E-4D65-A9CC-CA3B88A9926FQ36174265-1106074F-3B75-44A4-B593-3DC438B997C4Q36325362-AEB4132F-DFB4-4FFC-9588-C76359135956Q36406310-1DABAA0C-0CD6-43F8-BFD6-BF442BC44B99Q36657589-83B354C6-3E2C-46C2-93DD-1B1D7DF86BC5
P2860
Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Validation of bupropion hydrox ...... e P450 2B6 catalytic activity.
@en
type
label
Validation of bupropion hydrox ...... e P450 2B6 catalytic activity.
@en
prefLabel
Validation of bupropion hydrox ...... e P450 2B6 catalytic activity.
@en
P2093
P1476
Validation of bupropion hydrox ...... me P450 2B6 catalytic activity
@en
P2093
C M Lindley
E L Lecluyse
R M Laethem
S R Faucette
P304
P577
2000-10-01T00:00:00Z